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Abstract
Background: Guidelines for primary prevention of cardiovascular disease provide little guidance on how patients’
preferences should be taken into account. We wanted to explore whether general practitioners (GPs) are sensitive
to patient preferences regarding survival gains from statin therapy.
Methods: In a cross sectional, online survey 3,270 Norwegian GPs were presented with a 55 year old patient with
an unfavourable cardiovascular risk profile. He expressed preferences for statin therapy by indicating a minimum
survival gain that would be considered a substantial benefit. This survival gain varied across six versions of the
vignette: 8, 4 and 2 years, and 12, 6 and 3 months, respectively. Participants were randomly allocated to one
version only. We asked whether the GPs would recommend the patient to take a statin. Subsequently we asked
the GPs to estimate the average survival gain of life long simvastatin therapy for patients with a similar risk profile.
Results: We received 1,296 responses (40 %). Across levels of survival gains (8 years to 3 months) the proportion of
GPs recommending statin therapy did not vary significantly (OR per level 1.07, 95 % CI 0.99 to 1.16). The GP’s own
estimate of survival gain was a statistically significant predictor of recommending therapy (OR per year adjusted for
the GPs’ age, sex, speciality attainment and number of patients listed 3.07, CI 2.55 to 3.69).
Conclusion: GPs were insensitive to patient preferences regarding survival gain when recommending statin
therapy. The GPs' recommendations were strongly associated with their own estimates of survival gain.
Background
Shared decision making is recommended when treat-
ments have benefits and harms that people value differ-
ently [1]. Arguably the decision to initiate statin therapy
for primary prevention of cardiovascular disease is a
preference sensitive decision [2]. Benefits in terms of
gains in quality and length of life in the long run must
be weighed against potential harms such as side effects
and disease labelling in the present. To facilitate shared
decision making, conversations between doctors and pa-
tients should clarify the benefits and risks involved as
well as patients’ values and preferences [3].
Informing patients about benefits of risk reducing drug
therapies is not a trivial task. Studies of lay peoples’
hypothetical decisions suggest that they may find it
difficult to evaluate traditional effect measures such as
relative risk reduction [4] and number needed to treat
[5, 6]. Alternatively, benefits can be explained in terms
of gains in life expectancy or postponement of adverse
events [7], and such effect measures may be easier to
evaluate [8, 9]. More recently it has been shown that pa-
tients were less likely to redeem statin prescriptions when
informed about the benefits in terms of survival gains ra-
ther than absolute risk reduction [10]. Others have shown
that many physicians overestimate survival gains from sta-
tin therapy, and those physicians were more likely to rec-
ommend such therapy [11, 12].
Guidelines for primary prevention of cardiovascular
disease provide tools for risk calculation and decision
thresholds for preventive drug therapy [13], but there is
not much guidance about how patients’ values and pref-
erences should be taken into account. We wanted to ex-
plore whether general practitioners (GPs) are sensitive
to the patients’ preferences when considering statin
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therapy. Specifically, we tested the hypothesis that the
proportion of GPs recommending such therapy would
vary by the survival gain a hypothetical patient would re-
quire for the therapy to be considered worthwhile.
Methods
Participants
In December 2009 3,270 GPs registered with the Norwe-
gian Medical Association were sent an e-mail asking
them to participate in an online survey. We aimed to in-
clude all GPs in Norway at the time (n = 4,049, Table 1),
but a random sample of GPs, who were invited to another
survey taking place at the same time, were excluded. Thus
a random sample comprising 81 % of all Norwegian GPs
were invited. The online questionnaire was administered
by the Institute for Studies of the Medical Profession, a
small independent research unit hosted by the Norwegian
Medical Association. Return of the questionnaire was con-
sidered as consent to participate in the study.
Procedure
The questionnaire presented Mr. Hansen, a physically
fit, non-smoking male aged 55 who consulted his GP for
measurement of blood pressure and cholesterol because
his father had suffered a heart attack at age 52. Mr.
Hansen had no symptoms, but elevated blood pressure
(160/90 mmHg) and total cholesterol (7.5 mmol/liter).
He received dietary advice, but after three months his
risk profile was virtually unchanged (Fig. 1) with a ten year
absolute risk of cardiovascular death estimated at 7 – 10
in 100 patients. According to current Norwegian guide-
lines statin therapy is indicated in this situation, but there
was no reference to the guidelines in the scenario. At the
end of the scenario Mr. Hansen stated that he was
happy with his life and wanted it to last as long as pos-
sible. He would prefer achieving this through exercise
and reasonably healthy diet, but would consider drug
therapy if the benefit was substantial. Finally we
quantified the survival gain that the patient regarded as
substantial. We had six versions of the scenario, where
this survival gain was set at 3, 6 and 12 months and 2, 4
and 8 years, respectively. The GPs were randomly allo-
cated to one scenario only. We asked the GPs whether
they would recommend statin therapy for Mr. Hansen.
Possible response options were “certainly”, “probably”,
“probably not” and “certainly not”. Subsequently they were
asked to estimate the average survival gain of life long sim-
vastatin therapy for patients like Mr. Hansen. Possible re-
sponse categories were <12, 12, 18, 24, 30, 36, 42, 48 and
>48 months, respectively. Due to the low number of re-
spondents in some of the categories we collapsed these
into five groups in the analysis (<12 months, 12 or 18, 24
or 30, 36 or 42 and 48 or more months, respectively).
For other study purposes the questionnaire had ques-
tions about what professional activities the GPs consid-
ered meaningful and preferences for practice
organisation and remuneration (presented elsewhere,
[14, 15]).
Outcome measures
Our primary hypothesis was that more GPs would rec-
ommend statin therapy when the survival gain that Mr.
Hansen required was shorter. Consequently, the propor-
tion of GPs recommending statin therapy was our pri-
mary outcome measure. Although the survey provided
the GPs with a 4 graded response, we dichotomized this
variable when we analyzed the survey data so that “cer-
tainly” and “probably” were counted as “yes”, whereas
“probably not” and “certainly not” were counted as ”no”.
Analysis of this variable as a 4-point response instead of
as a dichotomous response yielded similar results, but
for ease of understanding, we present the results with
the responses grouped as described. We also tested
whether recommending statin therapy was associated
with the GPs’ estimate of survival gain for patients like
Mr. Hansen. For this analysis we included age, sex,
Table 1 Respondent characteristics among general practitioners randomised to six versions (A-F)a of a vignette portraying a patient
with an unfavourable cardiovascular risk profile
Group Mean age Proportion female Mean # of patients listed Specialty attainment
A 47 84/236 (36 %) 1222 149/237 (63 %)
B 48 77/211 (37 %) 1188 150/214 (70 %)
C 47 64/203 (32 %) 1242 138/203 (68 %)
D 48 85/225 (38 %) 1216 156/226 (69 %)
E 47 81/220 (37 %) 1175 139/220 (63 %)
F 47 78/208 (38 %) 1213 130/208 (63 %)
All Norwegian GPs n = 4,049b 49c 35%c 1182c 55%d
aThe vignettes differed with respect to the survival gain the patient would require to consider simvastatin therapy worthwhile (A: 3 months, B: 6 months, C:
12 months, D: 2 years, E: 4 years, F: 8 years)
bStatistics Norway (http://www.ssb.no accessed 24th of March 2011)
chttps://helsedirektoratet.no/Documents/Statistikk%20og%20analyse/Fastlegestatistikk/Fastlegestatistikk%20hovedtallsrapport-2010.pdf
dhttp://www.legeforeningen.no/id/18 14.04.2011
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speciality attainment and number of patients listed as
potential confounders.
Statistical analysis
We used logistic regression analyses to test for linear
trend across response options. Power calculation was
not performed as we aimed for a large sample for other
study purposes. SPSS (19.0) was used for data analysis.
In Norway studies like ours do not require evaluation by
an ethical research committee, but the study was approved
by the Norwegian Social Science Data Services, which is
the privacy ombudsman for all Norwegian universities as
well as the Institute for Studies of the Medical Profession
of the Norwegian Medical Association.
Results
Study sample
Of the 3,270 GPs invited 1,308 returned the online ques-
tionnaire, and 1,296 provided a recommendation regarding
statin therapy for Mr Hansen (response rate 40 %). The
respondents were fairly representative of Norwegian GPs
with respect to age (mean 47 years, 95 % CI 46 to 48), sex
(36 % females, CI 33 to 39) and number of patients listed
(mean 1209, CI 1189 to 1229), although the total popula-
tion of Norwegian GPs was slightly older (mean 49 years)
and has slightly fewer patients listed (mean 1182, see
Table 1). The proportion with specialty attainment was
somewhat higher among the respondents (66 %, CI 63
to 68) than among Norwegian GPs in general (55 %).
Responses to the scenarios
Across the six levels of survival gains that Mr. Hansen
required to regard the benefit as worthwhile (8 years to
3 months), the proportions of GPs recommending statin
therapy varied from 76 % to 87 %. A test for linear trend
across the levels was not statistically significant (OR per level
1.07, CI 0.99 to 1.16, Table 2). The average survival gain of
simvastatin therapy for patients like Mr Smith was correctly
estimated at <12 months by 25 % of the GPs. About half of
these GPs recommended statin therapy for Mr Hansen,
compared to more than 80 % of GPs who thought the aver-
age survival gain was 12 months or more (Table 2). In logis-
tic regression analysis the GP’s estimate of survival gain was
a statistically significant predictor of recommending statin
therapy for Mr Hansen. The OR adjusted for the GPs’ age,
sex, speciality attainment, and number of patients listed, was
3.07 (CI 2.55 to 3.69) per year (Table 2). There were no
statistically significant associations between recommending
statin therapy and age, sex, specialty attainment and number
of patients listed, respectively (data not shown).
Discussion
Summary
We observed that when considering statin therapy GPs
were insensitive to a hypothetical patient’s preferences in
Fig. 1 Risk profile of Mr. Hansen – a hypothetical 55 year old patient with a family history of premature coronary heart disease
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terms of the survival gain required to make therapy
worthwhile. The GPs’ recommendations were strongly
associated with their own estimates of average survival
gain for such patients, and the majority of GPs overesti-
mated the survival gain.
Strengths and limitations
The main strengths of this study are the large and fairly
representative sample of Norwegian GPs and the rando-
mised design. Although our response rate was modest
(40 %), it is comparable to other online surveys of busy
clinicians [16]. However, there are several limitations.
First, this was a study of hypothetical as opposed to real
life recommendations. Whether vignette studies like
ours may be representative of real life practice has been
a long standing concern [17], although there are some
studies in support of their validity [18–21]. Second, each
GP was presented with only one scenario. Offering more
scenarios could have reminded the GPs that patients
differ, and perhaps increased their sensitivity to patient
preferences. Third, the vignette did probably not capture
all that matters when GPs and patients consider statin
therapy for primary prevention. For example, in addition
to gains in life expectancy, delay in onset of symptoms
may also be important. Others have shown that personal
experience with cardiovascular disease may be as import-
ant as medication effectiveness, and that possible side ef-
fects, general dislike of taking medication and preferences
for life style changes may be important reasons to decline
preventive drug therapies [22]. Furthermore it is prob-
ably unusual for patients to state preferences in terms
survival gains, and GPs may not be familiar with this
benefit measure.
Comparison with existing literature
In a previous study Lytsy and co-workers [12] also ob-
served that GPs tended to overestimate the survival gain
of statin therapy, and that those who did were more
likely to recommend therapy. Our study adds to this evi-
dence by introducing patient preferences in the study.
Surveys of lay people suggest that when risk reduction is
explained in terms of survival gain it may be easier to
evaluate compared to traditional measures for risk reduc-
tions [8, 9]. Also, both a survey [23] and a randomised
clinical trial suggest that the amount of survival gain from
statin therapy matters to patients [10]. Although such ef-
fect measures are perhaps not much used in clinical prac-
tice yet, tables of gains in life expectancy tailored to
individual risk profiles have been published [7, 24].
Implications for practice and research
Our study suggests that the GPs’ own perceptions of
benefit get more weight than patient preferences when
considering statin therapy for primary prevention. Al-
though potentially in conflict with the practice of shared
decision making, this is not necessarily wrong. If, how-
ever, these recommendations are based on inflated per-
ceptions of benefit, it would raise some concern. It is
noteworthy that although current Norwegian guidelines
recommend statin therapy for patients like Mr. Hansen,
GPs who correctly estimated the survival gain at less
than 12 months [7, 24] were less likely to comply with the
guidelines. Future studies could explore whether GPs are
sensitive to the patients’ assessment of treatment effective-
ness when expressed in terms of more traditional effect
measures such as absolute or relative risk reduction, or in
terms of qualitative statements such as “this treatment
effect is good (or bad)”. Besides varying preferences for
treatment effectiveness, patients may differ with respect to
preferences regarding risk of side effects [22, 25], taking
pills [22], desire to participate in decision making [25],
and also with respect to the social context in which deci-
sions are made [26]. Further insight into whether and how
GPs take the patient perspective [26] into account when
considering statin therapy could be important to under-
stand enablers and barriers for shared decision making in
this area.
Conclusion
Our findings suggest that GPs may be insensitive to pa-
tient preferences regarding survival gain when recom-
mending statin therapy. On the other hand the GPs'
Table 2 Proportion of GPs recommending simvastatin therapy
by patients’ required survival gain to make therapy worthwhile,
and physicians’ perception of survival gain
Variable Proportion (%) Odds ratio for
trend (95 % CI)
Patient’s required survival
gain
1.07 (0.99 to 1.16)a
8 years 170/205 (83)
4 years 167/219 (76)
2 years 173/222 (78)
12 months 165/203 (81)
6 months 168/213 (79)
3 months 204/234 (87)
Physician’s perception of
survival gain
3.07 (2.55 to 3.69)b
<12 months 166/328 (51)
12 or 18 months 260/317 (82)
24 or 30 months 211/228 (93)
36 or 42 months 117/122 (96)
48 months or more 269/275 (98)
an = 1,296
bAdjusted for the GPs’ age, sex, specialty attainment and number of patients
listed. n = 1,217 due to missing responses
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own estimates of survival gain were strongly associated
with their recommendations.
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